89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on liver and cardiometabolic disease therapies, announced the approval of inducement grants for three new employees. The Compensation Committee approved non-qualified stock options to purchase 64,750 shares of common stock on September 1, 2025.
The grants, made under the company's 2023 Inducement Plan, will vest over four years, with 25% vesting after one year and the remainder vesting in 12 quarterly installments. The exercise price equals the closing price of 89bio's stock on the grant date. These grants comply with Nasdaq Listing Rule 5635(c)(4) and serve as employment inducements.
89bio (Nasdaq: ETNB), una società biofarmaceutica in fase clinica focalizzata su terapie per malattie del fegato e cardiometaboliche, ha annunciato l'approvazione di grant di incentivazione per tre nuovi dipendenti. Il Compensation Committee ha approvato opzioni su azioni non qualificate per l'acquisto di 64.750 azioni di capitale sociale il 1° settembre 2025.
I grant, concessi ai sensi del piano di incentivazione 2023 della società, matureranno in un periodo di quattro anni, con il 25% che matura dopo un anno e il restante che matura in 12 rate trimestrali. Il prezzo di esercizio è pari al prezzo di chiusura delle azioni di 89bio alla data di concessione. Queste assegnazioni sono conformi alla Nasdaq Listing Rule 5635(c)(4) e sono finalizzate come incentivi all'assunzione.
89bio (Nasdaq: ETNB), una compañía biofarmacéutica en fase clínica centrada en terapias para enfermedades hepáticas y cardiometabólicas, anunció la aprobación de otorgamientos de incentivo para tres nuevos empleados. El Comité de Compensación aprobó opciones sobre acciones no calificadas para comprar 64.750 acciones ordinarias el 1 de septiembre de 2025.
Los otorgamientos, realizados bajo el Plan de Incentivos 2023 de la compañía, se consolidarán a lo largo de cuatro años, con un 25% que se consolida tras un año y el resto en 12 cuotas trimestrales. El precio de ejercicio equivale al precio de cierre de las acciones de 89bio en la fecha de concesión. Estos otorgamientos cumplen la Norma de Cotización de Nasdaq 5635(c)(4) y sirven como incentivos de contratación.
89bio (Nasdaq: ETNB), 간 및 심장대사 질환 치료제에 주력하는 임상 단계의 바이오제약사인 이 회사는 세 명의 신입 사원에 대한 유인(인덕스먼트) 부여 승인을 발표했습니다. 보상위원회는 2025년 9월 1일에 보통주 64,750주를 매수할 수 있는 비적격 스톡옵션을 승인했습니다.
회사의 2023 인덕스먼트 플랜에 따라 이루어진 이 부여는 4년에 걸쳐 베스팅되며, 1년 후 25%가 베스트되고 나머지는 12회의 분기별 할부로 베스트됩니다. 행사 가격은 부여일 기준 89bio 주식의 종가와 동일합니다. 이 부여는 Nasdaq 상장 규정 5635(c)(4)에 부합하며 고용 유인책으로 제공됩니다.
89bio (Nasdaq: ETNB), une société biopharmaceutique en phase clinique spécialisée dans les traitements des maladies hépatiques et cardiométaboliques, a annoncé l'approbation d'attributions d'incitation pour trois nouveaux employés. Le comité de rémunération a approuvé des options d'achat d'actions non qualifiées pour acquérir 64 750 actions ordinaires le 1er septembre 2025.
Les attributions, effectuées en vertu du Plan d'incitation 2023 de la société, seront acquises sur une période de quatre ans, 25 % étant acquis après un an et le reste par versements trimestriels en 12 échéances. Le prix d'exercice est égal au cours de clôture de l'action 89bio à la date d'attribution. Ces attributions sont conformes à la règle de cotation Nasdaq 5635(c)(4) et servent d'incitations à l'embauche.
89bio (Nasdaq: ETNB), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Schwerpunkt auf Leber- und kardiometabolischen Erkrankungen, gab die Genehmigung von Anreizzuteilungen für drei neue Mitarbeiter bekannt. Das Vergütungskomitee genehmigte am 1. September 2025 nicht qualifizierte Aktienoptionen zum Kauf von 64.750 Aktien des Stammkapitals.
Die Zuteilungen, die im Rahmen des Inducement-Plans 2023 des Unternehmens erfolgen, werden über vier Jahre unverfallbar, wobei 25% nach einem Jahr und der Rest in 12 vierteljährlichen Raten unverfallbar werden. Der Ausübungspreis entspricht dem Schlusskurs der 89bio-Aktie am Zuteilungsdatum. Diese Zuteilungen entsprechen der Nasdaq-Listing-Regel 5635(c)(4) und dienen als Anreize zur Einstellung.
- None.
- None.
SAN FRANCISCO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 64,750 shares of the Company’s common stock to three new employees (the “Inducement Grants”) on September 1, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The Company is in Phase 3 trials for its lead candidate, pegozafermin, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis, including patients with compensated cirrhosis, and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The Company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the Company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
Eva Bilange
89bio, Inc.
eva.bilange@89bio.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
What stock options did 89bio (ETNB) grant to new employees in September 2025?
What is the vesting schedule for 89bio's September 2025 inducement grants?
Why did 89bio (ETNB) issue these stock options in September 2025?
What is the exercise price for 89bio's September 2025 inducement grants?
